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Abstract: 
Background: Approximately 5–10% of gastric cancers (GCs) have a 
fibroblast growth factor receptor-2 (FGFR2) gene amplification. AZD4547 is 
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a selective FGFR-1, 2, 3 tyrosine kinase inhibitor with potent preclinical 
activity in FGFR2 amplified gastric adenocarcinoma SNU16 and SGC083 
xenograft models. The randomized Phase II SHINE study (NCT01457846) 
investigated whether AZD4547 improves clinical outcome versus paclitaxel 
as second-line treatment in patients with advanced gastric adenocarcinoma 
displaying FGFR2 polysomy or gene amplification detected by fluorescence 
in situ hybridization.  
 
Patients and Methods: Patients were randomized 3:2 (FGFR2 gene 
amplification) or 1:1 (FGFR2 polysomy) to AZD4547 or paclitaxel. Patients 
received AZD4547 80 mg twice daily, orally, on a 2 weeks on/1 week off 
schedule of a 21-day cycle or intravenous paclitaxel 80 mg/m2 
administered weekly on Days 1, 8, and 15 of a 28-day cycle. The primary 
end point was progression-free survival (PFS). Safety outcomes were 
assessed and an exploratory biomarker analysis was undertaken.  
 
Results: Of 71 patients randomized (AZD4547 n = 41, paclitaxel n = 30), 
67 received study treatment (AZD4547 n = 40, paclitaxel n = 27). Among 
all randomized patients, median PFS was 1.8 months with AZD4547 and 
3.5 months with paclitaxel (one-sided p-value = 0.9581); median follow-up 
duration for PFS was 1.77 and 2.12 months, respectively. The incidence of 
adverse events was similar in both treatment arms. Exploratory biomarker 
analyses revealed marked intratumor heterogeneity of FGFR2 amplification 
and poor concordance between amplification/polysomy and FGFR2 mRNA 
expression.  
 
Conclusions: AZD4547 did not significantly improve PFS versus paclitaxel 
in gastric cancer FGFR2 amplification/polysomy patients. Considerable 
intratumor heterogeneity for FGFR2 gene amplification and poor 
concordance between FGFR2 amplification/polysomy and FGFR2 expression 
indicates the need for alternative predictive biomarker testing. AZD4547 
was generally well tolerated.  
  
 
 
Page 1 of 38 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
   
1 
 
Original Article 1 
A randomized, open-label study of the efficacy and safety of AZD4547 2 
monotherapy versus paclitaxel for the treatment of advanced gastric 3 
adenocarcinoma with FGFR2 polysomy or gene amplification  4 
E. Van Cutsem
1*
, Y-J. Bang
2*
, W. Mansoor
3
, R. Petty
4
, Y. Chao
5
, D. Cunningham
6
, 5 
D.R. Ferry
7¶
, N.R. Smith
8
, P. Frewer
9
, J. Ratnayake
8
, P. K. Stockman
8
, E. Kilgour
8
, & D. 6 
Landers8 7 
1
Digestive Oncology, University Hospitals Leuven and KU Leuven, Belgium; 
2
Biomedical 8 
Research Institute, Seoul National University College of Medicine, Korea; 
3
The Christie NHS 9 
Foundation Trust, Manchester, UK; 4Medical Research Institute, University of Dundee, 10 
Dundee, UK; 
5
Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; 11 
6Gastrointestinal and Lymphoma Unit, Royal Marsden Hospital NHS Foundation Trust, 12 
Surrey, UK; 7Clinical Oncology, New Cross Hospital, Wolverhampton, UK; 8Oncology 13 
Innovative Medicines and Early Development, AstraZeneca, Macclesfield, UK; 
9
 Oncology 14 
Innovative Medicines and Early Development,, AstraZeneca, Cambridge, UK 15 
*Contributed equally 16 
¶
Current affiliation: Eli Lilly and Company, Bridgewater, NJ, USA 17 
Corresponding author:  18 
Professor Eric Van Cutsem 19 
Digestive Oncology 20 
University Hospitals Leuven and KU Leuven 21 
Herestraat 49 22 
3000 Leuven  23 
Belgium 24 
Tel: +32 16 3 44218 25 
Page 2 of 38Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
   
2 
 
Fax: +32 16 3 44419 26 
Email: eric.vancutsem@uzleuven.be   27 
Running title: AZD4547 in gastric cancer with FGFR2 polysomy/amplification (59/60 max 28 
characters) 29 
  30 
Page 3 of 38 Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
   
3 
 
 31 
Key message (400/400 max characters incl. spaces) 32 
The selective fibroblast growth factor receptor [FGFR]-1, 2, 3 tyrosine kinase inhibitor, 33 
AZD4547, failed to improve progression-free survival versus paclitaxel in gastric 34 
adenocarcinoma patients displaying FGFR2 polysomy or gene amplification. Intratumor 35 
heterogeneity of FGFR2 amplification and poor concordance with FGFR2 expression 36 
highlight the need for alternative predictive biomarker testing.  37 
Page 4 of 38Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
   
4 
 
Abstract [285/300 words] 38 
Background: Approximately 5–10% of gastric cancers (GCs) have a fibroblast growth factor 39 
receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine kinase 40 
inhibitor with potent preclinical activity in FGFR2 amplified gastric adenocarcinoma SNU16 41 
and SGC083 xenograft models. The randomized Phase II SHINE study (NCT01457846) 42 
investigated whether AZD4547 improves clinical outcome versus paclitaxel as second-line 43 
treatment in patients with advanced gastric adenocarcinoma displaying FGFR2 polysomy or 44 
gene amplification detected by fluorescence in situ hybridization. 45 
Patients and Methods: Patients were randomized 3:2 (FGFR2 gene amplification) or 1:1 46 
(FGFR2 polysomy) to AZD4547 or paclitaxel. Patients received AZD4547 80 mg twice daily, 47 
orally, on a 2 weeks on/1 week off schedule of a 21-day cycle or intravenous 48 
paclitaxel 80 mg/m2 administered weekly on Days 1, 8, and 15 of a 28-day cycle. The primary 49 
end point was progression-free survival (PFS). Safety outcomes were assessed and an 50 
exploratory biomarker analysis was undertaken. 51 
Results: Of 71 patients randomized (AZD4547 n = 41, paclitaxel n = 30), 67 received study 52 
treatment (AZD4547 n = 40, paclitaxel n = 27). Among all randomized patients, median PFS 53 
was 1.8 months with AZD4547 and 3.5 months with paclitaxel (one-sided p-value = 0.9581); 54 
median follow-up duration for PFS was 1.77 and 2.12 months, respectively. The incidence of 55 
adverse events was similar in both treatment arms. Exploratory biomarker analyses revealed 56 
marked intratumor heterogeneity of FGFR2 amplification and poor concordance between 57 
amplification/polysomy and FGFR2 mRNA expression. 58 
Conclusions: AZD4547 did not significantly improve PFS versus paclitaxel in gastric cancer 59 
FGFR2 amplification/polysomy patients. Considerable intratumor heterogeneity for FGFR2 60 
gene amplification and poor concordance between FGFR2 amplification/polysomy and 61 
FGFR2 expression indicates the need for alternative predictive biomarker testing. AZD4547 62 
was generally well tolerated.  63 
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ClinicalTrials.gov identifier: NCT01457846 64 
Key words: AZD4547, clinical efficacy, fibroblast growth factor receptor, gastric cancer, 65 
fluorescence in situ hybridization   66 
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Introduction 67 
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are instrumental in a number of 68 
normal biologic processes, and their dysregulation by mechanisms including activating gene 69 
mutations, gene amplification and gene fusions, is believed to drive human cancers, including 70 
gastric cancer (GC) [1–3]. Approximately 5–10% of gastric tumors have an FGFR2 71 
amplification [4, 5], which appears to confer poor prognosis [5–7].  72 
AZD4547 is a selective FGFR-1, 2, 3 tyrosine kinase inhibitor that has displayed potent 73 
activity in preclinical studies. Cell lines of gastric adenocarcinoma possessing FGFR2 74 
amplification were sensitive to AZD4547, resulting in reduced cell proliferation and cell 75 
death [8]. Additionally, AZD4547 induced rapid tumor regression in two in vivo models of 76 
FGFR2-amplified GC [8].  77 
The primary hypothesis of the SHINE study was that AZD4547 has the potential to provide 78 
clinical benefit in patients with advanced gastric adenocarcinoma with tumors displaying 79 
FGFR2 polysomy or gene amplification selected by centralized fluorescence in situ 80 
hybridization (FISH) testing. Exploratory biomarker analyses were performed to further 81 
assess FGFR2 amplification heterogeneity within tumor sections and concordance with 82 
FGFR2 expression.  83 
  84 
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Materials and Methods 85 
Study design and patient selection  86 
SHINE was a multicenter, randomized, open-label study performed in 56 centers in Asia, 87 
North America, and Europe (ClinicalTrials.gov registration: NCT01457846; National Cancer 88 
Institute protocol ID: D2610C00004).  89 
Patients were recruited with locally advanced or metastatic GC with radiologically-confirmed 90 
progression after one prior chemotherapy regimen. Tumors were required to display either 91 
FGFR2 polysomy or amplification determined from archival tumor block or fresh tumor 92 
biopsy. Patients with prior exposure to AZD4547 or any other FGFR inhibitor were excluded. 93 
Patients in the FGFR2 amplification cohort were randomized 3:2 to AZD4547 or paclitaxel. 94 
Patients in the FGFR2 polysomy cohort were randomized 1:1 to AZD4547 or paclitaxel.  95 
Tumor FGFR status was determined by centralized FISH screening using a non-commercial 96 
kit (DAKO). FGFR2 amplification and polysomy were classified as follows:  97 
• FGFR2 amplification: FGFR2/Spectrum Green-labeled centromere of chromosome 98 
10 (CEN10) ratio ≥2 or FGFR2 gene clusters in ≥10% tumor cells 99 
• High polysomy: FGFR2/CEN10 ratio <2 and ≥4 copies of FGFR2 in ≥40% tumor 100 
cells 101 
• Low polysomy: FGFR2/CEN10 ratio <2 and ≥4 copies of FGFR2 in 10–39% tumor 102 
cells. 103 
The amplified cohort was further stratified into ‘low’ (FGFR2/CEN10 ratio ≥2 and <5) or 104 
‘high’ (FGFR2/CEN10 ratio ≥5) strata. Subsequent changes to the scoring system are detailed 105 
in the supplementary Material.  106 
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All patients gave written informed consent. The study was approved by the Institutional 107 
Review Board/Independent Ethics Committee at each study center and conducted in 108 
accordance with the Declaration of Helsinki. 109 
Treatment schedule 110 
Patients received either AZD4547 80 mg twice daily (BID), orally, on a 2 weeks on/1 week 111 
off schedule of a 21-day cycle or paclitaxel 80 mg/m2 as a 1-hour intravenous infusion weekly 112 
on Days 1, 8, and 15 of a 28-day cycle. The dosing strategy for AZD4547 was based on a 113 
phase I dose-escalation study [9, 10]. 114 
Assessments 115 
Patients underwent Response Evaluation Criteria In Solid Tumors (RECIST) assessments 116 
(ver. 1.1) at baseline and every 8 weeks thereafter using computerized tomography or 117 
magnetic resonance imaging. All assessments were carried out at the local sites and were not 118 
confirmed centrally. 119 
Pharmacokinetic (PK) assessments included changes in blood-borne biomarkers (phosphates, 120 
basic fibroblast growth factor [bFGF], and FGF23. Ad erse events (AEs) and clinical 121 
laboratory values were monitored throughout the study.  122 
End points 123 
The primary end point was progression free survival (PFS). Secondary end points included 124 
overall survival (OS), objective response rate (ORR), change in tumor size at 8 weeks, and the 125 
percentage of patients without progressive disease at 8 weeks.  126 
Interim analysis 127 
Prompted by slow recruitment, AstraZeneca and the Safety Review Committee agreed that it 128 
would be appropriate to conduct an unscheduled interim analysis of efficacy (based on 129 
average change in tumor size) and tolerability data. The results did not show superiority of 130 
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AZD4547 over paclitaxel in patients with advanced GC tumors with FGFR2 amplification 131 
and a decision was made to cease enrollment and close the study. 132 
Exploratory biomarker analysis 133 
FGFR2 expression in ribonucleic acid (RNA) extracted from tumor samples was analyzed 134 
using the nCounter® platform (NanoString Technologies®, Inc., Seattle, WA, USA).  135 
For heterogeneity analysis, FISH-stained sections were scanned into the MIRAX Panoramic 136 
250 Flash II (3D Histech) scanner at 40× magnification in the x, y, and z planes and analyzed 137 
using custom HALO v1.9 software (Indica Labs). All cells within the tumor compartment 138 
were classified as amplified or non-amplified, based on target:control probe ratio thresholds 139 
(FGFR2:CEN10 probe signals where ratio <2.0 = non-amplified and ratio ≥2.0 = amplified) 140 
and a visual heterogeneity map generated. 141 
 142 
Statistical analysis 143 
PFS, OS and ORR in all randomized patients were analyzed using Cox proportional hazards 144 
models with covariates for FGFR2 strata and treatment. PFS, OS and ORR within FGFR2 145 
strata were estimated from Cox proportional hazards models fitted in the overall population 146 
with covariates for FGFR2 stratum, treatment, and the treatment by FGFR2 stratum 147 
interaction.  The effect of AZD4547 on change in tumor size in all randomized patients, and 148 
within each of the FGFR2 strata, was estimated from an analysis of covariance (ANCOVA) 149 
model that included terms for baseline tumor size (log transformed), time from baseline scan 150 
to randomization, FGFR2 stratum, treatment and the treatment by FGFR2 interaction, where 151 
appropriate.  152 
  153 
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Results 154 
Participants 155 
A total of 960 patients had to be pre-screened for FGFR2 status to enable 71 patients to be 156 
randomized (AZD4547 n = 41 [57.7%]; paclitaxel n = 30 [42.3%]; full analysis set (FAS); 157 
Figure 1). FISH re-scoring to detect FGFR2 amplification identified three patients in the FAS 158 
who no longer met polysomy or amplification criteria and were excluded from the efficacy 159 
analysis that included FGFR2 stratum as a factor in the statistical model. 160 
Treatment groups were generally well balanced with respect to demographic characteristics 161 
(supplementary Table S1).  162 
Efficacy 163 
PFS and disease outcome 164 
Disease progression was reported in 36 of the 38 patients (94.7%) in the AZD4547 arm and 165 
26 of the 30 patients (86.7%) in the paclitaxel arm.  166 
In the FAS, median PFS was 1.8 months in the AZD4547 arm and 3.5 months in the 167 
paclitaxel arm, with a median duration of follow-up of 1.77 months and 2.12 months, 168 
respectively (see Table 1 for amplified and polysomy cohorts). The difference in PFS was not 169 
statistically significant in favor of AZD4547 at the one-sided 10% level (p-value from Cox 170 
proportional hazards model=0.9581). The observed hazard ratio (HR) was 1.57 (80% CI, 171 
1.12–2.21) for AZD4547 compared with paclitaxel (Figure 2).  172 
The observed HRs for the polysomy and amplified groups were 1.87 (80% CI, 1.17–3.06) and 173 
1.30 (80% CI, 0.81–2.12), respectively. No statistically significant difference in PFS in favor 174 
of AZD4547 was observed for AZD4547 versus paclitaxel in either the polysomy or 175 
amplified groups (one-sided p-values of 0.9562 and 0.7590, respectively).  176 
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Complete response was not reported in any patient (Table 2). In the overall population, the 177 
ORR was 2.6% in the AZD4547 arm and 23.3% in the paclitaxel arm (0% and 20.0%, 178 
respectively [amplified cohort] and 5.0% and 26.7%, respectively [polysomy cohort]). The 179 
difference in ORR was not statistically significant in favor of AZD4547 at the one-sided 10% 180 
level (odds ratio 0.09, 80% CI, 0.02–0.35, one-sided p-value=0.9970). 181 
There were a total of 27 deaths (71.1%) in the AZD4547 arm and 18 deaths (60.0%) in the 182 
paclitaxel arm. In the FAS, median OS was 5.5 and 6.6 months for AZD4547 and paclitaxel 183 
arms, respectively, with a median duration of follow-up of 4.8 months and 5.1 months, and 184 
the difference in OS was not statistically significant (Figure 3; HR 1.31; 80% CI, 0.89–1.95, 185 
one-sided p-value=0.8156). In the amplified and polysomy cohorts, there was no difference 186 
between treatment groups in terms of median OS (Table 1: HR 1.26; 80% CI, 0.72–2.25, one-187 
sided p-value=0.7006 for the amplified cohort, and HR 1.36; 80% CI, 0.80–2.38, one-sided p-188 
value=0.7697 for the polysomy cohort).  189 
Analysis of the percentage change in tumor size at Week 8 did not show any statistically 190 
significant difference in favor of the AZD4547 arm compared with the paclitaxel arm 191 
(difference 39.44; 80% CI, 25.18–55.33, one-sided p-value=0.9999). Similar results were 192 
observed in the amplified (difference 39.21; 80% CI, 19.43–62.26, one-sided p-value=0.9965) 193 
and polysomy (difference 39.68; 80% CI, 19.38–63.45, one-sided p-value=0.9961) cohorts. 194 
Safety 195 
For those patients who received treatment, the median total duration of treatment was 196 
50.5 days in the AZD4547 arm and 57.0 days in the paclitaxel arm. AEs and serious AEs 197 
related to study treatment occurred at similar rates in both treatment arms (supplementary 198 
Table S2).  199 
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Biomarker analysis 200 
PK findings were consistent with previous studies of AZD4547 [9] (see Supplementary 201 
Materials; Figure S1).  202 
FGFR2 expression was assessed by nanostring analysis of RNA from 73 archival tumor 203 
samples, comprised of 56 tumor samples from patients randomized to AZD4547 or paclitaxel 204 
(n = 35 and n = 21, respectively), and an additional 17 samples from pre-screened patients 205 
who were not randomized (FGFR2 copy number normal [CNN]). Overall, the analysis set 206 
consisted of 24 amplified, 29 polysomy, and 20 CNN samples.  207 
A range of overlapping FGFR2 expression levels were observed between the amplified and 208 
non-amplified tumor samples (Figure 4A), with only 6/24 amplified tumors having elevated 209 
FGFR2 expression and, of these, only 5 having expression levels overlapping with SNU16- 210 
and KATOIII FGFR2-amplified GC cell lines, which are highly sensitive to AZD4547 211 
induced growth inhibition [11]. There was no evidence of elevated FGFR2 expression outside 212 
the amplified cohort (Figure 4A).  213 
FGFR2 amplification was assessed in sections from seven tumor samples from the high 214 
amplification (FGFR2:CEN10 ratio >5) AZD4547 arm, as this represented the patient group 215 
most likely to respond to treatment. As a benchmark, image analysis of a tumor section from 216 
the AZD4547-sensitive SNU16 tumor xenograft model revealed that 100% of tumor cells 217 
displayed FGFR2 amplification with a mean FGFR2:CEN10 ratio of 38. In the seven patient 218 
tumor sections examined, the number of tumor cells ranged from approximately 1500 to 219 
>41000, and representative FISH-stained sections revealed marked sub-clonal heterogeneity, 220 
with between 8% and 70% of the tumor cells displaying FGFR2 amplification (Figure 4B). 221 
However, there was no clear correlation between the extent of sub-clonal heterogeneity and 222 
tumor shrinkage in response to AZD4547 (Figure 4C).  223 
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Exploratory survival analysis 224 
Details of the exploratory survival analysis of non-randomized patients who underwent FISH 225 
pre-screening in the SHINE study are shown in Supplementary Materials (Figure S2). 226 
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Discussion 227 
The efficacy of paclitaxel monotherapy in the SHINE study was consistent with data from 228 
other studies in a second-line setting. Median PFS and OS in the paclitaxel arm was similar to 229 
outcomes reported previously [12–16]. The trend towards shorter PFS and OS observed in the 230 
FGFR2 amplified group, is in agreement with earlier studies in patients with FGFR2 231 
amplification [5–7].  232 
In the current study, AZD4547 was not superior to paclitaxel, in contrast to preclinical 233 
findings [8, 17]. The poor association between FGFR2 amplification and elevated FGFR2 234 
expression observed in the SHINE study, together with marked sub-clonal heterogeneity of 235 
FGFR2 amplification in tumor sections, contrasts markedly with the high and homogenous 236 
amplification and high FGFR2 expression observed in the SNU16 model. Although no 237 
correlation was observed between the level of sub-clonal heterogeneity and tumor shrinkage, 238 
the failure to adequately enrich for clonally amplified tumors is likely to be a factor in the 239 
failure to translate the preclinical efficacy of AZD4547 to the clinic and this is supported by 240 
results from a translational clinical study in which patients with high and clonal FGFR2 241 
amplification responded to AZD4547 [18]. It is possible that a high threshold exists for 242 
clonality of FGFR2 amplification to sensitize to AZD4547.  243 
Heterogeneity of gene amplification does not necessarily result in lack of clinical efficacy as 244 
HER2 amplification and expression is heterogeneous in GC [19], yet patients with HER2 245 
amplification benefit from treatment with trastuzumab [20]. Hence the impact of 246 
heterogeneity on the predictive nature of a gene amplification biomarker may be target 247 
dependent. A limitation of this study is that the archival diagnostic tissue samples screened by 248 
FISH and the FGFR2 status may not reflect the status of metastatic tumor sites at study entry. 249 
Clearly tumors with FGFR2 amplification leading to elevated FGFR2 expression do exist, but 250 
this appears to be at a very low prevalence. Consequently, there is a need for alternative 251 
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predictive biomarker testing to more effectively enrich for this population prior to assessment 252 
of FGFR therapies. 253 
Elevated plasma phosphate is a pharmacodynamic marker of interrupting FGF23 signaling 254 
through FGFR inhibition in the kidney [21, 22] and has been observed for other FGFR 255 
inhibitors [23, 24]. The intermittent dosing schedule allowed for elevations in plasma 256 
concentrations of phosphate during the on-drug period to normalize during the off-drug 257 
period.  258 
This study illustrates the considerable operational challenge associated with recruitment of 259 
low prevalence patient groups into clinical studies. Centralized FISH testing identified 260 
patients with FGFR2 amplification at an actual prevalence of 9%. However, attrition between 261 
FISH pre-screening and randomization resulted in an operational prevalence of 1%. Follow-262 
up of screened patients showed a trend for FGFR2 amplification being associated with poor 263 
prognosis which may have contributed to the higher than expected attrition rate.  264 
The AE profiles for AZD4547 and paclitaxel were consistent with their known pharmacologic 265 
effects. The AZD4547 80 mg BID 2 weeks on/1 week off schedule was well tolerated and no 266 
new safety signals were identified compared with previous studies [9, 11, 25].  267 
Conclusion 268 
Treatment with AZD4547 did not improve PFS compared with paclitaxel in the overall 269 
population or in patients with FGFR2 amplification or polysomy according to FISH selection. 270 
The safety profile demonstrated that AZD4547 is generally well tolerated. Exploratory 271 
analysis revealed discordance between FGFR2 expression and FGFR2 amplification in 272 
gastric tumors selected using focal FISH testing, which to a large extent reflected 273 
considerable intratumor heterogeneity. Failure to enrich for a clonally amplified population 274 
may have contributed to the failure of the SHINE study to demonstrate superiority of 275 
AZD4547 compared with paclitaxel. 276 
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Figure legends 377 
Figure 1. CONSORT diagram. FAS, full analysis set; FGFR2, fibroblast growth receptor-2. 378 
Figure 2. Progression-free survival Kaplan-Meier plots (FAS): overall population (A), 379 
FGFR2 polysomy population (B), and FGFR2 amplification population (C). BID, twice daily; 380 
FGFR2, fibroblast growth receptor-2. 381 
Figure 3. Overall survival Kaplan-Meier plot (FAS) overall population (A), FGFR2 382 
polysomy population (B), and FGFR2 amplification population (C). BID, twice daily; 383 
FGFR2, fibroblast growth receptor-2. 384 
Figure 4. Analysis of formalin-fixed, paraffin-embedded archival tumor samples from 385 
patients with advanced GC in SHINE showing: (A) FGFR2 expression (log2 normalized data) 386 
of archival tumor sections compared with amplified (SNU16, KATOIII, SUM52) and non-387 
amplified (AGS, SNU-216, SNU-620) cell lines; (B) in situ heterogeneity mapping of seven 388 
patient samples and an SNU16 GC xenograft section showing tissue classifications and binary 389 
heterogeneity maps (non-amplified = blue; amplified = orange) for a large representative field 390 
of view for each tumor. The table shows cell count, % amplification (based on ratio ≥2) and 391 
average ratio score; and (C) a waterfall plot showing best change in target lesion size for 392 
SHINE patients who received AZD4547.  FGFR2, fibroblast growth receptor-2; FISH, 393 
fluorescence in situ hybridization; GC, gastric cancer. 394 
 395 
 396 
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Table 1. Median PFS and OS stratified by FGFR2 low and high amplification, and polysomy (FAS).  
 AZD4547 Paclitaxel 
 Amplification 
(n = 38) 
Polysomy 
(n = 20) 
Amplification 
(n = 30) 
Polysomy 
(n = 15) 
 Total 
(n = 18) 
Low  
(n = 9)  
High 
(n = 9) 
 Total 
(n = 15) 
Low  
(n = 10) 
High 
(n = 5) 
 
PFS 
Median PFS (months) 1.5 1.4 2.0 1.9 2.3 1.9 3.7 3.5 
No. events 17 9 8 19 13 10 3 13 
Duration of follow-up (months) 1.46 - - 1.86 1.87 - - 3.52 
OS 
Median OS (months) 4.9 4.9 10.5 6.3 4.6 3.5 NC 7.2 
No. deaths 12 6 6 15 9 8 1 9 
Duration of follow-up (months) 3.0 2.0 3.4 6.0 3.9 3.5 6.5 6.6 
 
FAS, full analysis set; FGFR2, fibroblast growth factor receptor-2; NC, non-calculable; OS, overall survival; PFS, progression-free survival. 
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Table 2. Best objective response stratified by FGFR2 low and high amplification, and polysomy (FASa).  
  AZD4547 Paclitaxel 
  Low 
amplification 
(n = 9) 
High 
amplification 
(n = 9) 
Polysomy 
(n = 20) 
Low 
amplification 
(n = 10) 
High 
amplification 
(n = 5) 
Polysomy 
(n = 15) 
Response Complete response, n (%) 0 0 0 0 0 0 
 Partial response, n (%) 0 0 1 (5.0) 1 (10.0) 2 (40.0) 4 (26.7) 
Non-response Stable disease ≥8 weeks, n (%) 1 (11.1) 2 (22.2) 5 (25.0) 3 (30.0) 2 (40.0) 5 (33.3) 
 Progression, n (%) 
RECIST progression 
Death 
8 (88.9) 
6 (66.7) 
2 (22.2) 
6 (66.7) 
5 (55.6) 
1 (11.1) 
14 (70.0) 
13 (65.0) 
1 (5.0) 
6 (60.0) 
2 (20.0) 
4 (40.0) 
1 (20.0) 
1 (20.0) 
0 
4 (26.7) 
4 (26.7) 
0 
 Not evaluable, n (%) 0 1 (11.1) 0 0 0 2 (13.3) 
 
a
FISH re-scoring (removal of the cluster rule) to detect FGFR2 amplification resulted in the identification of three patients in the FAS who no longer met the 
criteria for polysomy or amplification.  
FAS, full analysis set; FGFR2, fibroblast growth factor receptor-2; FISH, fluorescence in situ hybridization; RECIST, Response Evaluation Criteria In Solid 
Tumors.  
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Supplementary Material 
Materials and Methods 
Fluorescence in situ hybridization (FISH) scoring system 
Tumor fibroblast growth factor receptor (FGFR) status was determined by centralized FISH screening 
with a scoring system similar to that used for epidermal growth factor receptor and human epidermal 
growth factor receptor 2 (HER2) [1]. Tumor sections were scanned at low magnification to identify 
areas of gene copy number gain and then 50 cell nuclei were counted.  
Due to the difficulties in consistently applying the scoring system for cluster definition the FISH 
scoring system was reviewed during the study and the cluster definition removed from the 
amplification category, hence the definition for FGFR2 amplification was refined to include only: 
FGFR2/CEN10 ratio ≥2. Tumor samples from all randomized patients were re-scored and patients 
who no longer met the criteria for amplification were excluded from the final analysis. 
Patients in the FGFR2 amplification cohort were randomized 3:2 to AZD4547 or paclitaxel, within 
the FGFR2 low- and high-level amplification strata. Patients in the FGFR2 polysomy cohort were 
randomized 1:1 to AZD4547 or paclitaxel.  
 
Results 
Participants 
Four patients were randomized but did not receive randomized treatment and therefore the modified 
intention-to-treat (mITT) and safety analysis population consisted of 67 patients (AZD4547 n = 40 
[59.7%], polysomy n = 20, amplification n = 17; paclitaxel n = 27 [40.3%], polysomy n = 14, 
amplification n = 13). Patients randomized to the two treatment groups were generally well balanced 
with respect to demographic characteristics (supplementary Table S1). 
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Safety 
AEs and serious AEs related to study treatment occurred at similar rates in both treatment arms 
(supplementary Table S2). Six (15%) patients in the AZD4547 arm experienced retinal pigmented 
epithelium detachment (RPED), with the majority of cases of Common Terminology Criteria for 
Adverse Events (CTCAE) Grade 1/2. No patients in the paclitaxel arm developed the condition. AEs 
related to study treatment that led to treatment discontinuation occurred in 2 patients in each arm 
(5.0% for AZD4547 and 7.4% for paclitaxel). Two patients in the AZD4547 arm and one patient in 
the paclitaxel arm experienced an AE (intestinal hemorrhage, arterial disorder, or asthenia) with an 
outcome of death. None of the deaths were considered by the investigator to be causally related to the 
study drug.  
 
Hematology and clinical chemistry  
The greatest incidences of changes classified as CTCAE Grade 3/4 were reported for leukocytes 
decreased (2 [5.0%] for AZD4547; 4 [15.4%] for paclitaxel), neutrophils decreased (4 [10.3%] for 
AZD4547; 4 [17.4%] for paclitaxel), lymphocytes decreased (6 [15.4%] for AZD4547; 3 [13.0%] for 
paclitaxel), alkaline phosphatase increased (5 [13.2%] for AZD4547; 2 [7.7%] for paclitaxel), and 
phosphate increased (4 [10.0%] for AZD4547; 1 [4.0%] for paclitaxel). 
Dose modification occurred more frequently in the AZD4547 arm (13 [32.5%] patients) compared 
with the paclitaxel arm (6 [22.2%] patients). Eleven (27.5%) patients in the AZD4547 arm and 5 
(18.5%) patients in the paclitaxel arm had their study dose interrupted. Five (12.5%) patients in the 
AZD4547 arm and 3 (11.1%) patients in the paclitaxel arm had dose reduction. The occurrence of an 
adverse event (AE) was the most common reason for dose modifications, dose reductions, and dose 
interruptions. 
Pharmacokinetic analysis 
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A clear increase in plasma phosphate levels was observed during cycles 1, 2, and 3 of AZD4547 
administration with a return to normal levels during the week off while no corresponding increase was 
observed with paclitaxel treatment (supplementary Figure S1). No significant changes from baseline 
were observed in plasma bFGF and FGF23 in either the AZD4547 or paclitaxel arm (data not shown). 
There was no apparent difference in AZD4547 exposure with respect to surgery versus no surgery and 
surgery type. PK data displayed high variability due, in part, to dose reductions in some patients from 
80 mg to 40 mg twice daily (BID).  
 
Exploratory survival analysis 
In agreement with previous reports [2–4], follow-up of non-randomized patients who underwent FISH 
pre-screening in the SHINE study showed a trend for FGFR2 amplification to be inversely correlated 
with overall survival. However this was not statistically significant by multivariate analysis 
(aggregated HR non-amplified versus amplified: 1.15 [0.81–1.63]; p = 0.437) (supplementary Figure 
S2). 
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Supplementary Figure legend 
Figure S1. Modulation of absolute plasma phosphate levels in the AZD4547 treatment arm during on- 
and off-drug periods (A) compared with the paclitaxel treatment arm (B).  
Figure S2. Overall probability of survival Kaplan-Meier plot by FGFR2 amplification and gene copy 
number analyzed by FISH; all pre-screened patients who were not randomized. Aggregated hazard 
ratio non-amplified versus amplified: 1.15 [0.81–1.63]; p = 0.437; multivariate analysis. FGFR2, 
fibroblast growth factor receptor-2; FISH, fluorescence in situ hybridization.  
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Table S1. Clinical characteristics and baseline demographics (FAS). 
 AZD4547  
(n = 41) 
Paclitaxel  
(n = 30) 
Total  
(n = 71) 
Male, n (%) 29 (70.7) 22 (73.3) 51 (71.8) 
Mean (SD) age, years 60.6 (11.4) 61.9 (10.7) 61.2 (11.0) 
Prior chemotherapy
a
 
 Capecitabine 
 Cisplatin 
 Fluorouracil 
 Oxaliplatin 
 Epirubicin 
   
23 (56.1) 15 (50.0) 38 (53.5) 
21 (51.2) 
15 (36.6) 
15 (36.6) 
11 (26.8) 
18 (60.0) 
9 (30.0) 
7 (23.3) 
9 (30.0) 
39 (54.9) 
24 (33.8) 
22 (31.0) 
20 (28.2) 
Number of prior 
chemotherapy regimens 
 1 
 2 
 3 
 
 
34 (82.9) 
5 (12.2) 
0 
 
 
24 (80.0) 
2 (6.7) 
1 (3.3) 
 
 
58 (81.7) 
7 (9.9) 
1 (1.4) 
Prior surgical procedures 
 Gastrectomy 
 
15 (36.6) 
 
8 (26.7) 
 
23 (32.4) 
Overall disease classification 
 Metastatic
a
 
  Respiratory 
  Hepatic
b
 
  Lymph nodes 
  Peritoneum 
 
40 (97.6) 
10 (24.4) 
25 (61.0) 
21 (51.2) 
8 (19.5) 
 
30 (100) 
5 (16.7) 
15 (50.0) 
18 (60.0) 
10 (33.3) 
 
70 (98.6) 
15 (21.1) 
40 (56.3) 
39 (54.9) 
18 (25.4) 
 Locally advanced 1 (2.4) 0 1 (1.4) 
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aReported in ≥10 patients; bIncluding gall bladder. 
Other lung/liver classifications not included within the ‘respiratory’ or ‘hepatic’ disease 
classifications: lung (n = 1), lung and liver metastases (n = 1), liver (n = 1), lung and pleura 
metastases (n=1), lung, liver, mediastinum (n=1). 
FAS, full analysis set; SD, standard deviation.  
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Table S2. AEs reported in ≥10% of patients in either treatment arm (safety analysis; n = 67).  
 AZD4547  
(n = 40) 
Paclitaxel  
(n = 27) 
Any AE causally related to study treatment, n (%) 29 (72.5) 19 (70.4) 
Any AE of CTCAE Grade ≥3 causally related to study treatment, n (%) 7 (17.5) 5 (18.5) 
Any SAE causally related to study treatment, n (%) 1 (2.5) 1 (3.7) 
Decreased appetite, n (%) 16 (40.0) 8 (29.6) 
Asthenia, n (%) 11 (27.5) 5 (18.5) 
Nausea, n (%) 10 (25.0) 6 (22.2) 
Constipation, n (%) 10 (25.0) 5 (18.5) 
Stomatitis, n (%) 10 (25.0) 2 (7.4) 
Abdominal pain, n (%) 9 (22.5) 5 (18.5) 
Upper abdominal pain, n (%) 9 (22.5) 0 
Dry mouth, n (%) 9 (22.5) 0 
Vomiting, n (%) 8 (20.0) 5 (18.5) 
Anemia, n (%) 7 (17.5) 6 (22.2) 
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Increased aspartate aminotransferase, n (%) 7 (17.5) 0 
Fatigue, n (%) 6 (15.0) 8 (29.6) 
Diarrhea, n (%) 6 (15.0) 6 (22.2) 
Dysgeusia, n (%) 6 (15.0) 4 (14.8) 
Retinal pigment epithelium detachment, n (%) 6 (15.0) 0 
Increased alanine aminotransferase, n (%) 6 (15.0) 0 
Peripheral edema, n (%) 4 (10.0) 2 (7.4) 
Pyrexia, n (%) 4 (10.0) 2 (7.4) 
Dyspepsia, n (%) 4 (10.0) 1 (3.7) 
Headache, n (%) 4 (10.0) 1 (3.7) 
Increased blood alkaline phosphatase, n (%) 4 (10.0) 1 (3.7) 
Dry eye, n (%) 4 (10.0) 0 
Alopecia, n (%) 2 (5.0) 13 (48.1) 
Neutropenia, n (%) 2 (5.0) 9 (33.3) 
Insomnia, n (%) 2 (5.0) 3 (11.1) 
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Back pain, n (%) 1 (2.5) 6 (22.2) 
Peripheral neuropathy, n (%) 1 (2.5) 4 (14.8) 
Lower respiratory tract infection, n (%) 0 3 (11.1) 
Myalgia, n (%) 0 3 (11.1) 
Peripheral sensory neuropathy, n (%) 0 3 (11.1) 
 
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious adverse event.  
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